

Appendix Table F35. Continence after different doses of duloxetine

Reference sample size	Outcome as reported	Daily dose mg/day	Events in active group/randomized to active	Events in control group/randomized to control	Relative risk (95% CI)	Absolute risk difference (95% CI)
Norton, 2002 ³⁵⁵ 275	SPT ≤2G	20mg/day vs. 40mg/d	110/138	111/137	0.98 (0.88; 1.11)	-0.01 (-0.11; 0.08)
Norton, 2002 ³⁵⁵ 275	Negative CST	20mg/day vs. 40mg/d	112/138	112/137	0.99 (0.89; 1.11)	-0.01 (-0.10; 0.09)
Norton, 2002 ³⁵⁵ 275	Zero incontinent episodes of diary	20mg/day vs. 40mg/d	128/138	123/137	1.03 (0.96; 1.11)	0.03 (-0.04; 0.10)
Norton, 2002 ³⁵⁵ 278	SPT ≤2G	20mg/day vs. 80mg/d	110/138	113/140	0.99 (0.88; 1.11)	-0.01 (-0.10; 0.08)
Norton, 2002 ³⁵⁵ 278	Negative CST	20mg/day vs. 80mg/d	112/138	114/140	1.00 (0.89; 1.12)	0.00 (-0.09; 0.09)
Norton, 2002 ³⁵⁵ 278	Zero incontinent episodes of diary	20mg/day vs. 80mg/d	128/138	123/140	1.06 (0.98; 1.14)	0.05 (-0.02; 0.12)
Norton, 2002 ³⁵⁵ 277	SPT ≤2G	40mg/day vs. 80mg/d	111/137	113/140	1.00 (0.90; 1.13)	0.00 (-0.09; 0.10)
Norton, 2002 ³⁵⁵ 277	Negative CST	40mg/day vs. 80mg/d	112/137	114/140	1.00 (0.90; 1.12)	0.00 (-0.09; 0.09)
Norton, 2002 ³⁵⁵ 277	Zero incontinent episodes of diary	40mg/day vs. 80mg/d	123/137	123/140	1.02 (0.94; 1.11)	0.02 (-0.05; 0.09)